NJ-LTTS
22.9.2022 12:01:36 CEST | Business Wire | Press release
L&T Technology Services Limited (BSE: 540115, NSE: LTTS), a global leading pure-play engineering services company, today announced the launch of the first-ever Digital Engineering Awards, in association with Information Services Group (ISG), a leading global technology research and advisory firm, and business news channel CNBC TV18 in India.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220921006059/en/
The Digital Engineering Awards will recognize outstanding leaders with innovative approaches that maximize performance and value across the entire lifecycle of an asset, and lead to a more sustainable future (Graphic: Business Wire)
The Digital Engineering Awards recognize outstanding leaders who challenge the status quo with innovative approaches that maximize performance and value across the entire lifecycle of an asset, and lead to a more sustainable future.
Enterprises and their service providers are invited to submit nominations through October 15, with winners announced during a gala awards celebration to be held in December in the U.S. Enterprise award winners, selected by a global panel of industry experts, will be named in nine categories – five team awards and four individual awards:
Engineering the Change Team Awards |
Engineering at Heart Individual Awards |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amit Chadha, Chief Executive Officer and Managing Director, L&T Technology Services Limited, said, “The need of the hour is dominated by demand for continuous evolution, driven by disruptive innovations. Given the rapid transformational disruptions across the industry, Digital Engineering has become more prominent than ever. Through the pioneering Digital Engineering Awards, our endeavor is to provide a platform that brings together global leaders, thus leading to new industry benchmarks and innovations.”
Michael P. Connors, Chairman and Chief Executive Officer, ISG, said, “Digital Engineering is now a top priority for companies looking to compete in an increasingly digitized, intelligent and networked global marketplace. Through an interconnected ecosystem of platforms, devices and data, this discipline enables companies to create new business models, deliver superior customer experiences and achieve operational efficiencies on a scale never before imagined. We are delighted to partner with LTTS and CNBC to recognize outstanding achievements in this space.”
Shivakumar S, Chief Operating Officer, Branded Content Business at Network 18, said, “The ER&D industry is a true sunrise sector, responsible for digital transformations on a global scale. Digital Engineering is leading to shorter product lifecycles, smarter products and solutions, paperless factories, and a host of other notable innovations. The Digital Engineering Awards will play an important role in celebrating and showcasing such new-age technology success stories. We believe we are the ideal media partner for the awards, given the strength of our brands CNBC-TV18 and Moneycontrol, which have been informing audiences in business, technology and retail for more than two decades now in India.”
About the Digital Engineering Awards
The Digital Engineering Awards bring together industry leaders to recognize outstanding achievements in the R&D domain, and to help global organizations give shape to their transformative ideas. The Awards have been launched by L&T Technology Services in association with ISG, with CNBC TV18 as a media partner. For more about the Awards, visit this website or contact us at info@digitalengineeringawards.com.
About L&T Technology Services Ltd
L&T Technology Services Limited is a listed subsidiary of Larsen & Toubro Limited focused on Engineering and R&D (ER&D) services. We offer consultancy, design, development and testing services across the product and process development life cycle. Our customer base includes 69 Fortune 500 companies and 57 of the world’s top ER&D companies, across industrial products, medical devices, transportation, telecom & hi-tech, and the process industries. Headquartered in India, we have over 21,400 employees spread across 19 global design centers, 28 global sales offices and 89 innovation labs as of June 30, 2022. For more information, please visit https://www.ltts.com/
About ISG
ISG (Information Services Group) (Nasdaq: III) is a leading global technology research and advisory firm. A trusted business partner to more than 800 clients, including more than 75 of the world’s top 100 enterprises, ISG is committed to helping corporations, public sector organizations, and service and technology providers achieve operational excellence and faster growth. The firm specializes in digital transformation services, including automation, cloud and data analytics; sourcing advisory; managed governance and risk services; network carrier services; strategy and operations design; change management; market intelligence and technology research and analysis. Founded in 2006, and based in Stamford, Conn., ISG employs more than 1,300 digital-ready professionals operating in more than 20 countries—a global team known for its innovative thinking, market influence, deep industry and technology expertise, and world-class research and analytical capabilities based on the industry’s most comprehensive marketplace data. For more information, visit www.isg-one.com.
About Network18
Network18 Media & Investments Limited (Network18 Group) is one of India's most diversified media and entertainment (M&E) conglomerates, with interests across television, digital content, filmed entertainment, e-commerce, print and allied businesses. TV18 Broadcast Limited, a subsidiary of Network18, manages its primary business of broadcasting. It runs the largest news network in India, spanning business news general news, and regional news. Our marquee brands like CNBC-TV18, News18 India, and CNN News18 are part of this news bouquet. For the Indian diaspora and audiences across the globe, News18 International delivers definitive Indian news. For more information, visit: https://www.nw18.com/corporate.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220921006059/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom